Judge Questions Eagle's Orphan Drug Market Exclusivity
A D.C. Circuit judge appeared unconvinced by Eagle Pharmaceuticals' assertion that Congress unambiguously gave the U.S. Food and Drug Administration discretion to grant orphan drug exclusivity to multiple sponsors of a...To view the full article, register now.
Already a subscriber? Click here to view full article